← Back to Screener
Polaryx Therapeutics, Inc. Common Stock (PLYX)
Price$6.12
Favorite Metrics
Price vs S&P 500 (4W)0.98%
Market Capitalization$289.74M
All Metrics
Price vs S&P 500 (YTD)-84.63%
10-Day Avg Trading Volume0.16M
EPS (Annual)$-0.64
ROI (Annual)-644.23%
Cash / Share (Quarterly)$0.12
ROA (Last FY)-607.00%
Cash Flow / Share (Annual)$-0.05
P/B Ratio54.66x
Net Income / Employee (Annual)$-3
EPS Incl Extra (Annual)$-0.64
Current Ratio (Annual)17.30x
Quick Ratio (Quarterly)8.65x
3-Month Avg Trading Volume2.10M
52-Week High$48.91
EPS Excl Extra (Annual)$-0.64
Quick Ratio (Annual)15.99x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.77x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.10
ROE (Last FY)-644.23%
EPS Basic Excl Extra (Annual)$-0.64
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Year-to-Date Return-82.51%
5-Day Price Return-0.81%
EPS Normalized (Annual)$-0.64
Month-to-Date Return-19.05%
EBITD / Share (Annual)$-0.64
Beta-5.73x
52-Week Low$2.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PLYXPolaryx Therapeutics, Inc. Common Stock | — | — | — | — | $6.12 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Polaryx Therapeutics is a clinical-stage biotech company developing oral small molecule therapies for rare pediatric lysosomal storage diseases (LSDs). Its pipeline includes PLX-200, PLX-300, and PLX-100, designed to address the underlying pathophysiology of these genetic disorders. The company focuses on disease-modifying treatments that target core mechanisms common to multiple LSDs.